Showing 1501-1510 of 1692 results for "".
- Promising Results Reported for Oral Therapy for Obstructive Sleep Apneahttps://practicalneurology.com/news/promising-results-reported-for-oral-therapy-for-obstructive-sleep-apnea/2474868/Treatment with AD109 (Apnimed, Cambridge, MA), an investigational oral therapy for obstructive sleep apnea (OSA), was found to significantly reduce the apnea-hypopnea index (AHI) at 26 weeks (P=.001), according to topline results from the phase 3 SynAIRgy clinical study (NCT05813275). AD109 treat
- Lecanemab, an Antibody to Amyloid Beta, Reduced Amyloid Levels and Cognitive Declinehttps://practicalneurology.com/news/lecanemab-an-antibody-to-amyloid-beta-reduced-amyloid-levels-and-cognitive-decline/2469653/Preliminary assessment of results clinical trials of lecanemab (BAN2401; Biogen, Cambridge, MA; Eisai, Tokyo, Japan) for potential treatment of Alzheimer disease (AD), were presented at the Alzheimer’s Association International Conference July 26-30, 2021. Lecanemab reduced brain
- Cases of Dementia Projected to Increase Worldwidehttps://practicalneurology.com/news/cases-of-dementia-projected-to-increase-worldwide/2469646/Data presented at the Alzheimer's Association International Congress July 26-30, 2021 show that all types of dementia have been on the rise in recent years and are predicted to increase further. Rates of early-onset dementia are also increasing, and in the US, mortality from Alzheimer diseae
- Healthy Midlife Choices May Reduce Risk of Stroke in Womenhttps://practicalneurology.com/news/healthy-midlife-choices-may-reduce-risk-of-stroke-in-women/2469224/A study published in Stroke shows better eating habits, maintaining a healthy weight, exercising, and not smoking beginning at midlife may still significantly reduce stroke risk. During the 26-year follow-up, researchers found: • smoking cessation, da
- Metabolic Regulator Shows Promise for Life-Saving Treatment of Thymidine Kinase Deficiency Disordershttps://practicalneurology.com/news/metabolic-regulator-shows-promise-for-life-saving-treatment-of-thymidine-kinase-deficiency-disorders/2469047/In a global phase 2 study of pyrimidine nucleoside substrate enhancement therapy (SET) (MT1621; Modis Therapeutics/Zogenix, Oakland, CA) for treating thymidine kinase 2 (TK2) deficiency all treated participants survived. Most individuals treated with SET had improved (68%) or stabilized (26%) mot
- First Participant Dosed in Phase 2 Trial of Phosphodiesterase Inhibitor AR1001 for Alzheimer's Diseasehttps://practicalneurology.com/news/first-participant-dosed-in-phase-2-trial-of-phosphodiesterase-inhibitor-ar1001-for-alzheimers-disease/2468777/The first patient has been dosed in a phase 2 study evaluating safety and efficacy of AR1001 (AR1001; AriBio, San Diego, CA). A novel phosphodiesterase inhibitor, AR1001, is being investigated for treatment of Alzheimer’s disease (AD). The 26-week double-blind placebo-controlled stu
- Study Shows Minimally Invasive Laser Ablation Provides Freedom from Epileptic Seizureshttps://practicalneurology.com/news/study-shows-minimally-invasive-laser-ablation-provides-freedom-from-epileptic-seizures/2468942/In a recent study published in Epilepsia, 80% of people treated with laser interstitial thermal therapy (LITT) for mesial temporal lobe epilepsy (mTLE) were seizure free or almost seizure free (Engel 1 or Engel 2 cl
- Last Patient Fully Assessed in Trial of Accordion Formulation of Levodopa/Carbidopa for Parkinson's Diseasehttps://practicalneurology.com/news/last-patient-fully-assessed-in-trial-of-accordion-formulation-of-levodopacarbidopa-for-parkinsons-disease/2468878/The final patient completed their last physician visit in a pivotal phase 3 clinical trial for the accordion pill formulation of carbidopa/levodopa (AP-CD/LD) (Intec Pharma, Jerusalem, Israel) for treating advanced Parkinson’s disease (PD). A gastric-retentive drug delivery sy
- One-Year Data from OCARINA II Show Suppression of Relapses/Lesions in MS with Subcutaneous Ocrevus Treatmenthttps://practicalneurology.com/news/one-year-data-from-ocarina-ii-show-suppression-of-relapseslesions-in-ms-with-subcutaneous-ocrevus-treatment/2470456/Data from the OCARINA II study (NCT05232825) presented at the American Academy of Neurology (AAN) 2024 Annual Meeting showed that subcutaneous (SC) injection of Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) resulted in near-complete suppression of clinical relapses and brain lesions i
- Neurologic Recovery After Severe COVID-19 Leaves One-Third With Worsening Cognitive Symptoms at 12 Monthshttps://practicalneurology.com/news/neurologic-recovery-after-severe-covid-19-leaves-one-third-with-worsening-symptoms-at-12-months/2469977/Among individuals who were admitted to the intensive care unit with COVID-19, outcomes were worse for those who had neurologic symptoms both in hospital and over 12 months after COVID-19 diagnosis, including cognitive deficits in 41%, regardless of whether they had neurologic symptoms while in th